Navidea Biopharma

Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. It operates through the following segments: Diagnostics, Therapeutics, and Corporate. The company was founded in 1983 and is headquartered in Dublin, OH.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

COLUMBUS, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced disappointing results of an exploratory analysis conducted on the Company's pivotal NAV3-33 clinical trial titled “Evaluation of Tc 99m Tilmanocept Imaging for the Early Prediction of Anti-TNFα Therapy Response in Patients with Moderate to Severe Active Rheumatoid Arthritis (R.

Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024

COLUMBUS, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will be hosting a virtual meeting of its stockholders at 1pm ET on Monday, July 8th, 2024. The purpose of the special meeting is to consider and vote upon (i) an amendment to the Company's certificate of incorporation to allow stockholders to act by written consent, and (ii.

Navidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024

COLUMBUS, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations.

Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release.

Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Announces NYSE American's Decision to Suspend Trading In Its Common Stock.

Navidea Biopharmaceuticals, Inc. Announces NYSE American's Decision to Suspend Trading In Its Common Stock

NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to suspend trading in the common stock of Navidea Biopharmaceuticals, Inc. (the “Company”) — ticker symbol NAVB — from the NYSE American. The staff suspended trading in the Company's common stock because the Listings Qualifications Panel (the “Panel”) of the Committee for Review of the Board of Directors of the Exchange (the “Committee”) had issued a.

NYSE American to Suspend Trading in Navidea Biopharmaceuticals, Inc. (NAVB)

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel.

Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities.

Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities

Navidea Biopharmaceutical (NYSEMKT: NAVB ) stock is falling on Monday after the biopharmaceutical company got a major delisting warning. The NYSE American LLC sent the company a notice about its failure to comply with listing standards.

Why Is Navidea Biopharmaceutical (NAVB) Stock Down 13% Today?

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination.

Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination

NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Navidea Biopharmaceuticals, Inc. (the “Company”) — ticker symbol NAVB —from the Exchange. NYSE Regulation has determined that the Company is no longer suitable for listing pursuant to Section 1009(a) of the NYSE American Company Guide (the “Company Guide”) as the Company was unable to demonstrate t.

NYSE American to Commence Delisting Proceedings Against Navidea Biopharmaceuticals, Inc. (NAVB)

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer.

Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced Dana J Moss, JD has joined the Company's Board of Directors, adding depth in legal advice, strategic business, life sciences and technology in line with Navidea's stated objectives and its Fix, Fund, Propel approach to advancing innovative technology to market. Separat.

Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down

ProPhase Labs

Navidea Biopharmaceuticals Inc. NAVB, -2.38% announced Friday that it had rejected an unsolicited ProPhase Labs Inc. PRPH, +0.08% offer for certain Navidea assets, saying the proposal undervalues Navidea and is not in the best interest of shareholders. ProPhase, a biotech, genomics and diagnostics company, said in a release Thursday that on June 8 it had offered $7 million in cash or $9.1 million in common stock for the assets, with the cash offer equivalent to over two times the then-current market cap of Navidea.

Navidea Biopharmaceuticals rejects ProPhase Labs offer

DUBLIN, Ohio--(BUSINESS WIRE)--Following the Company's Fix, Fund, Propel approach, the proposal substantially undervalues Navidea and is not in the best interests of stockholders.

Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series K Preferred Stock, par value $0.001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on June 27, 2.

Navidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common Stock

Cardinal Health

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment.

Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update.

Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it received a Notice (the “Notice”) on June 1, 2023 from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the continued listing standards as set forth in Section 1003(f)(v) of the NYSE American Company Guide (“Company.

Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L. Cappello Steps Down.

Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L.

DUBLIN, Ohio--(BUSINESS WIRE)--New Existing Navidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market.

Navidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer.

Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the introduction of a Fix, Fund, Propel approach to driving the Company's strategy forward; The Company will issue a press release detailing financial highlights and corporate developments in lieu of hosting conference call and webcast for the first quarter ended March.

Navidea Biopharmaceuticals, Inc. Drives Strategy Forward, Shifts Approach for Communications

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announces the execution of a letter of intent to sale the Cardinal Milestone Payment for $8 million and execution of a new $2.75 million Equity Line of Credit, led by a longtime Navidea investor, to provide substantial funding for the Company's Phase IIb (NAV3-32) and Phase III.

Navidea Biopharmaceuticals, Inc. Announces Intent to sell Cardinal Milestone Payment for $8 Million; Secures New $2.75 Million Equity Line of Credit

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it has signed an Asset Purchase Agreement allowing Meilleur Technologies, Inc.

News for Navidea Biopharma Stock (NAVB)